With increasing pricing pressures in a therapeutic area which has seen many recent drug approvals, diabetes drug developers are seeking to enhance their clinical development and portfolio. By leveraging Continuous Glucose Monitoring (CGM), sponsors conducting trails in diabetes as well as other indications have the potential to enhance patient safety, accelerate clinical development and increase commercial value.
Attend this live webinar to hear QuintilesIMS, in collaboration with key CGM opinion leaders, discuss the advantages of using CGM in your clinical trials.
Register for this webinar to learn:
Register today to understand how CGM captures near real-time glycemic data that can help enhance patient safety, accelerate clinical development and increase commercial value.
Erica Caveney, MD
Vice President, Global Head, Diabetes Center of Excellence
James R. Johnson, PhD
Principle Biostatistician and Pharmacokineticist
Poul Strange, MD, PhD
President and Medical Director
Integrated Medical Development